| Title: |
Effects of methotrexate on human osteoblasts in vitro: Modulation by 1,25‐dihydroxyvitamin D3 |
| Authors: |
Dr. Scheven, Ben A.A., van der Veen, Maaike J., Damen, Cora A., Lafeber, Floris P.J.G., van Rijn, Herman J.M., Bijlsma, Johannes W.J., Duursma, Sumen A. |
| Source: |
Journal of Bone & Mineral Research; June 1995, Vol. 10 Issue: 6 p874-880, 7p |
| Abstract: |
This study was designed to investigate whether methotrexate (MTX), used in the treatment of rheumatoid arthritis (RA), affects proliferation and differentiation of human osteoblasts in culture. The effects of MTX were assessed by analyzing markers of proliferation and differentiation of human trabecular bone–derived osteoblast‐like cells cultured in the presence or absence of 1,25‐dihydroxyvitamin D3(1,25[OH]2D3). Treatment of the osteoblastic cells with MTX resulted in a strong dose‐dependent inhibition of cell proliferation with half maximal response at a dose of 30 nM. MTX did not interfere with cellular alkaline phosphatase (AP) activity, the number of cells expressing cytochemical AP, or basal osteocalcin production. Addition of 1,25(OH)2D3to the cultures caused an enhanced AP expression and osteocalcin production coinciding with a decreased osteoblast proliferation. Coincubation of 1,25(OH)2D3with MTX in doses ≥100 nM further inhibited osteoblast growth and induced a significant stimulation of AP expression and activity, and production of osteocalcin above the values reached in the 1,25(OH)2D3cultures. In conclusion, MTX proved to be a potent inhibitor of osteoblast proliferation but did not affect basal osteoblastic phenotypic expression. In the presence of the osteoblast differentiation‐promotor, 1,25(OH)2D3, MTX further inhibited cell growth which was associated with enhanced AP activity and osteocalcin production. Thus, MTX may have profound effects on bone metabolism and remodeling by interfering with bone cell turnover. |
| Database: |
Supplemental Index |
